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Abstract: The aim of this study is to observe the influence of Medication-Related Osteonecrosis of 
the Jaw (MRONJ) on the physical and mental conditions of cancer patients using a Quality of Life 
(QoL) questionnaire during regular dental practice measures. Twenty cancer patients (8 males and 
12 females) with established MRONJ were enrolled in the “MoMax” (Oral Medicine and 
Maxillofacial) project of the Department of Oral Sciences and Maxillofacial Surgery at “Sapienza” 
University of Rome, and were included in the study. The 12-item Short Form Survey was used to 
evaluate the QoL. Statistical analysis revealed a significant difference for Mental Component 
Summary (MCS) scores based on age (p = 0.018). The regression analysis revealed that the Physical 
Component Summary (PCS) scores were negatively influenced by the anti-resorptive medication 
duration (p = 0.031 and β = −1.137). No significant differences were observed with the other variables 
considered. The QoL of cancer patients is generally deteriorated and MRONJ may cause a further 
negative impact. This study highlights the possible need to include psychosocial and physical 
evaluations in the management process of MRONJ in cancer patients. 
Keywords: bisphosphonates; Medication-Related Osteonecrosis of the Jaw; osteonecrosis; quality 
of life; SF-12 questionnaire 
 
1. Introduction 
Medication-Related Osteonecrosis of the Jaw (MRONJ) is defined as an exposed or probed bone 
persisting for more than eight weeks in the maxillofacial region in patients with ongoing or a history 
of treatment with bone-modifying agents or angiogenic inhibitor agents [1–3]. Despite the incidence 
of MRONJ being relatively low, it should be considered as a potentially serious and debilitating 
complication [4]. 
The cumulative incidence of MRONJ ranges from 1% to 9% of patients with advanced cancer 
[3]. Although about 40% of patients with MRONJ are non-cancer patients, the epidemiological data 
show that the risk is higher in cancer patients, with a prevalence between 0.2% and 6.7%. In 
comparison, the prevalence is between 0% and 0.4% in patients with osteometabolic diseases [2,4]. 
This may be due to the existence of a high number of patients affected by osteometabolic diseases 
worldwide [4,5]. 
MRONJ, as one of the oral complications associated with cancer treatment, negatively affects the 
physical appearance, speech, breathing, and swallowing of patients. This negative impact 
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correspondingly influences the Quality of Life (QoL) [6,7]. There is no totally approved treatment 
modality for MRONJ. Due to the nature of the disease and the general medical condition of this kind 
of patient, a palliative modality that decreases the symptoms has become one of the management 
modalities in many circumstances [8–10]. 
In cancer patients, traditional evaluations, such as measuring pain and symptoms for achieving 
the treatment goals, have become insufficient [11,12]. These kinds of evaluation do not provide the 
health provider with a comprehensive image of the patients’ psychosocial issues and all possible 
treatment benefits or side-effects. It may be inappropriate to consider relieving pain or survival as 
the goal of the treatment plan and neglect the physical and psychological status of the patients [12]. 
Additionally, it becomes a commitment for the dental team to tailor the dental management and 
prevention for cancer patients at risk of or with established MRONJ. 
In order to confront the lack of information, a questionnaire for QoL evaluation may be a useful 
instrument for gathering general information about the patients’ physical and psychological 
conditions. In particular, the most recommended source of data of the patient for the assessment of 
QoL is the patient themself [11,13,14]. 
In a recent systemic review, the existence of few studies evaluating the QoL of MRONJ patients 
was observed. The authors recommended carrying out further studies on this topic and proposed 
developing and validating a specific QoL questionnaire for this complication, which may act as a 
guide for future treatment strategies and decisions [15]. 
The aim of this study is to observe the influence of MRONJ on the physical and mental 
conditions of cancer patients through the use of a QoL questionnaire during regular dental practice 
measures. 
2. Experimental Section 
A cross-sectional study was carried out among cancer patients that volunteered to enroll in the 
“MoMax” (Oral Medicine and Maxillofacial) project of the Department of Oral Sciences and 
Maxillofacial Surgery at “Sapienza” University of Rome; this project is a task force that was founded 
in June 2014 and designed to provide cancer patients and patients with Oral Potentially Malignant 
Lesions (OPML) with multidisciplinary team care. The main aim of this project is to customize and 
accelerate the treatment plan for cancer patients as a trial to improve their survival rate. Different 
health providers cooperate in this project, including oral medicine specialists, prosthodontists, 
maxillofacial surgeons, oncologists, radiotherapists, and histo-pathologists. All procedures 
performed in the study involving human participants were in accordance with the ethical standards 
of the institutional and/or national research committee and the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. 
The inclusion criteria were patients with a confirmed diagnosis of cancer, current or a previous 
history of anti-resorptive or anti-angiogenic medications, established MRONJ with full clinical and 
radiographical investigations, and age ≥18 years old. Patients with the following criteria were 
excluded from the study: a history of radiotherapy, language difficulties, and mental disability. 
Twenty-six patients fulfilling the inclusion criteria presented themselves to our department from 
September 2017 to April 2018. Twenty patients (8 males and 12 females) agreed to participate in the 
study and signed an informed consent form. Six patients were excluded from the study: five patients 
refused to participate and one patient was excluded due to language difficulties. 
Full clinical and radiographical investigations, including Computed Tomography (CT), were 
carried out to achieve a definite diagnosis of MRONJ. The 12-item Short Form Survey (SF-12) version 
was used in this study. The SF-12 was administered in a face to face interview (including a health 
care worker and the patient) during their normal outpatient visit by the main researcher. 
SF-12 is a shortened version of SF-36. It consists of 12 items that measure eight scales, including 
physical functioning (2 items), role physical (2 items), body pain (1 item), general health (1 item), 
vitality (1 item), social functioning (1 item), role emotional (2 items), and mental health (2 items). The 
response to scales differs across and within the same scale. 
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The standard scoring algorithms were used to produce the Physical and Mental Component 
Summary (PCS and MCS, respectively) scores of the SF-12 questionnaire. The PCS and MCS scores 
are the two recommended valuable aggregate summary measures. Low PCS and MCS scores indicate 
low level of the health status [16]. 
The recorded variables were the age, gender, marital status, tumor (cancer or cancer with bone 
metastasis), anti-resorptive medication timing (past or current), active principle of the drug, method 
of administration (intravenous (I.V), intramuscular (I.M), subcutaneous (S.C), oral, or association), 
anti-resorptive duration (<3 years or >3 years), number of infusions (<8 infusions or >8 infusions), 
MRONJ stage (according to the American Association of Oral and Maxillofacial Surgeons (AAOMS) 
staging system), and localization (mandible, maxilla, or both). 
The data were analyzed statistically using the Statistical Package for the Social Sciences (SPSS) 
software for Windows, release 20.0. Mann–Whitney and Kruskal–Wallis tests were used for the 
quantitative variables to test the differences between groups. These non-parametric tests were chosen 
because the distribution of the various variable scores did not respect the assumptions of normality, 
as indicated by the skewness and kurtosis, and the Shapiro test. PCS and MCS scores were used as 
dependent variables for conducting the multiple linear regression analysis (Figures 1 and 2). The 
significance level was set at p < 0.05. 
 
Figure 1. Physical Component Summary (PCS) histogram (created by SPSS software for Windows, 
release 20.0). 
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Figure 2. Mental Component Summary (MCS) histogram (created by SPSS software for Windows, 
release 20.0). 
3. Results 
Twenty patients with an average age of 66 years old were included. Six cases (30%) included 
established MRONJ at stage 0, 2 cases (10%) included that at stage I, 11 cases (55%) included that at 
stage II, and 1 case (5%) included that at stage III. The localization of MRONJ was distributed as 
follows: 3 cases were in the maxilla (15%), 12 cases were in the mandible (55%), and 5 cases were in 
both (Table 1). The Mann–Whitney test revealed a significant difference for MCS based on age. The 
group of older patients showed lower median scores than those of younger patients (p = 0.018). No 
further significant differences were observed between the groups considered (gender, marital status, 
type of tumor, medication timing, active principle, method of administration, duration of therapy, 
MRONJ stage, and localization) regarding either the PCS scores or the MCS scores (Table 2). It was 
observed, through the regression analysis, that the PCS scores were negatively influenced by the anti-
resorptive medication duration. Patients who had been receiving treatment with anti-resorptive 
medications for less than three years showed higher PCS scores (p = 0.031 and β = −1.137). The other 
variables did not influence the dependent variables used (PCS and MCS) (Table 3, Figures 3 and 4). 
 
Figure 3. Physical Component Summary (PCS) in patients with a history of anti-resorptive medication 
duration <3 years. 
 
Figure 4. Physical Component Summary (PCS) in patients with a history of anti-resorptive medication 
duration >3 years.  
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Table 1. Study sample characteristics. 
Characteristics Distribution (%) 
Age  
Under 60  4 (20%) 
Over 60 16 (80%) 
Gender  
Male  8 (40%) 
Female 12 (60%) 
Marital status  
Single  5 (25%) 
Married 14 (70%) 
Tumor  
Cancer  8 (40%) 
Cancer with bone metastasis  12 (60%) 
Anti-resorptive medication timing 
Past  15 (75%) 
Current  5 (25%) 
Active principle  
Zoledronic acid 9 (45%) 
Clodronic acid  1 (5%) 
Alendronic acid  1 (5%) 
Denosumab (one dose every month)  3 (15%) 
Adalimumab  1 (5%) 
Combination  5 (25%) 
Method of administration  
I.V  11 (55%) 
I.M/S.C 5 (25%) 
Oral  1 (5%) 
Association  3 (15%) 
Anti-resorptive medications duration 
<3 years  8 (40%) 
>3 years  12 (60%) 
I.V. < 8 infusions  2 (10%) 
I.V. + 8 infusions  12 (60%) 
MRONJ stage  
0 6 (30%) 
I 2 (10%) 
II 11 (55%) 
III 1 (5%) 
Localization  
Maxilla 3 (15%) 
Mandible  12 (60%) 
Both 5 (25%) 
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Table 2. Median 12-item Short Form Survey (SF-12) component scores by patients’ characteristic 
variables. 
Variable n 
Score of PCS-12 
Median (min–max) 
p-
value  
Score of MCS-12 
Median (max–min) 
p-
value  
All the sample 20 53.6 (43.7–60.6)  28.6 (19.6–37.9)  
Age  0.06  0.018 
Under 60  4 48.8 (44.5–53.4)  31.9 (29.9–35.2)  
Over 60 16 56.2 (43.7–60.6)  27.4 (19.6–37.97)  
Gender  0.70  0.22 
Male  8 54.02 (43.7–60.3)  28.789 (26.2–37.97)  
Female 12 54.5 (44.5–60.6)  27.4 (19.6–35.2)  
Marital status  0.71  0.58 
Single  5 54.7 (43.8–60.1)  27.5 (25.4–37.97)  
Married 14 54.5 (44.5–60.6)  27.7 (19.6–35.2)  
Not declared  1 53.4  30.8  
Tumor  0.28  0.68 
Cancer  8 57.4 (50.2–60.1)  27.7 (24.4–29.7)  
Cancer with bone 
metastasis  
12 52.96 (44.5–60.6)  28.6 (19.6–37.97)  
Anti-resorptive medication timing  0.86  0.73 
Past  15 53.5 (43.7–60.6)  27.9 (19.6–37.97)  
Current  5 57.1 (45–60.1)  27.4 (25.4–35.2)  
Active principle  0.57  0.54 
Zoledronic acid 9 54.7 (43.7–60.6)  27.5 (19.6–37.97)  
Clodronic acid  1 57.1  28.8  
Alendronic acid  1 60.1  25.4  
Denosumab (one dose 
every month) 
3 57.8 (50.8–60.3)  27.9 (26.5–29.8)  
Adalimumab  1 53.5  23.6  
Combination  5 50.2 (45–59.4)  29.7 (26.3–35.2)  
Method of administration  0.38  0.38 
I.V  11 53.4 (43.7–60.6)  27.5 (19.6–37.97)  
I.M/S.C 5 57.1 (50.8–60.3)  27.9 (23.6–29.8)  
Oral  1 60.1  25.4  
Association  3 52.6 (45–59.4)  32.99 (27.4–35.2)  
Anti-resorptive medications duration  0.25  0.45 
<3 years  8 57.1 (50.2–60.3)  29.3 (26.6–37.97)  
>3 years  12 51.7 (47.7–60.6)  28.1 (19.6–35.2)  
I.V < 8 infusions  2 57.4 (55.4–59.4)  25.9 (24.4–27.4)  
I.V + 8 infusions  12 51.4 (43.7–60.6)  29.8 (19.6–37.97)  
MRONJ stage  0.85  0.15 
0 6 53.4 (46.8–60.1)  27.5 (23.6–30.8)  
I 2 51.4 (45–57.7)  31.4 (27.5–35.2)  
II 11 55.4 (43.7–60.6)  27.4 (19.6–34.5)  
III 1 54.7  37.97  
Localization  0.47  1.00 
Maxilla 3 54.1 (43.7–60.3)  27.438 (23.6–37.97)  
Mandible  12 57.8 (45–60.6)  27.9 (19.6–35.2)  
Both 5 54.3 (46.8–60.1)  28.2 (25.4–30.8)  
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Table 3. Multiple linear regression analysis. 
Variable 
PCS - 12 MCS - 12 
β p-value β p-value 
Age −0.188 0.55 −0.123 0.77 
Gender 0.632 0.15 −0.633 0.25 
Marital status 0.320 0.37 −0.136 0.76 
Anti-resorptive medication timing −0.830 0.08 1.018 0.09 
Anti-resorptive medications duration −1.137 0.03 0.471 0.32 
Number of infusions 0.715 0.10 −0.652 0.21 
MRONJ stage −0.007 0.98 0.410 0.31 
Localization 0.729 0.09 −0.643 0.21 
4. Discussion 
MRONJ is a serious drug-related complication characterized by progressive destruction of the 
bone of the mandible and/or maxilla. It may lead to psycho-functional deterioration and eventually 
a poor QoL due to the possible occurrence of structural damage, pain, and suppurations [17]. Bone-
modifying agents and angiogenic inhibitor agents are the causative drugs for MRONJ [3,13,16,18]. 
Although many pre-clinical and clinical studies on the pathogenesis of MRONJ have been 
carried out, the pathogenesis of the disease is not yet fully understood [19]. The collateral effects of 
drug administration, such as altered bone remodeling, the over-suppression of bone resorption, 
angiogenesis inhibition, the suppression of acquired immunity, vitamin D deficiency, and soft tissue 
bisphosphonate (BP) toxicity, have been suggested as an explanation of the unique localization of 
MRONJ. In addition, many co-factors, such as comorbidities (e.g., diabetes), smoking, dental 
interventions, and concurrent medications (e.g., corticosteroids), have been reported to play a role in 
the pathogenesis of MRONJ [19]. 
In a recent systemic review, it was found that the reported risk factors of this complication are 
missing uniformity. Some studies have only focused on the dental risk factors and others have only 
reported medical comorbidity risk factors [10]. The most commonly reported dental risk factor is 
dental extraction, while the most common medical comorbidity risk factor is chemotherapy 
(including hormone therapy and immunosuppressive therapy). Periodontal diseases and 
corticosteroid administration are the second most common reported risk factors [10]. 
A major risk for the development of MRONJ has been observed with I.V. bisphosphonates (BPs). 
Furthermore, oral BPs have been reported as a cause of MRONJ, but with a lower risk when 
compared to monthly I.V. BPs [1,2,20,21]. 
Numerous treatment protocols have been proposed, such as early conservative surgical 
approaches, extensive and radical surgical resections, and nonsurgical palliative protocols with the 
administration of long-term antibiotics [22,23]. However, there is no general approval for a specific 
intervention protocol. Although it has been demonstrated that some approaches have shown 
successful wound closure after the intervention, some reports have noted that these approaches may 
also cause worsening of the disease [2,9,22,23]. 
Some authors have suggested that success in MRONJ management can be considered in the case 
of the reduction of symptoms achieved by pain relief, infection control, and the prevention of further 
progression [9]. Consequently, many palliative protocols have been suggested as a trial to control this 
chronic complication, including hyperbaric oxygen, Photobiomodulation (PBM), and long-term 
antibiotics [8,9,23]. 
The involvement of a multidisciplinary team is an appropriate way of providing health care to 
cancer patients. A considerable impact on the clinical decision can be obtained by working as a team 
[24–27]. The nature of the disease, the absence of a fully approved treating modality, and the patient’s 
general medical condition have guided us in providing this kind of patient with multidisciplinary 
team care. Recently, the Multinational Association of Supportive Care in Cancer, International 
Society of Oral Oncology, and American Society of Clinical Oncology (MASCC, ISOO, and ASCO, 
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respectively) have proposed a clinical practice guideline for the management of MRONJ. In this 
guideline, they have recommended the coordination of care for patients with a risk of or established 
MRONJ through cooperation between dentists and oncologists in the form of multidisciplinary team 
care [3]. 
In our study, no correlation was observed between age and PCS scores. However, in the 
literature, the analysis of three large-scale population studies demonstrated that age was associated 
with the physical and mental health scores (PCS and MCS) of SF-12 questionnaire version one. With 
standard algorism scoring, a negative correlation between age and PCS scores and a positive 
correlation with MCS scores were noted [16,28]. 
The relation between QoL and MRONJ stages has been observed [15]. Worsening of the QoL 
was observed with stage II. Miksad et al., noticed that stage “I” showed a better QoL and was similar 
to the control group of patients with a history of bisphosphonates [29]. Capocci et al., demonstrated 
a significant difference in the physical and mental health scores between stages I and III [17]. 
In our study, no relation was observed between the MRONJ stages and the summary 
components considered. This may be due to the small number of cases and the unequal distribution 
of cases among stages of MRONJ. The majority of cases were stage II (55%) and only three cases (15%) 
were stages I and III. This also may be due to the presence of about 30% of cases with stage 0. 
We decided to include cases with MRONJ stage 0, because the AAOMS considers stage 0 to be 
a valid disease category. This is because the AAOMS has noted the presence of many studies that 
have demonstrated the progress of up to 50% of MRONJ cases from stage 0 to stage I, II, or III. 
According to the AAOMS staging system, stage 0 is considered in patients with no clinical 
necrotic bone, but with non-specific symptoms or clinical and radiographic findings [2]. 
Our study showed a possible relation between PCS and the anti-resorptive medication duration 
(> 3 years and < 3 years). However, it was observed that some cases with more than a three year 
duration of anti-resorptive medication showed higher physical health scores. This may be due to the 
nature of MRONJ, as there are many other risk factors that may play a role in worsening the patient’s 
condition, such as the method of administration, the type of administrated drug, comorbidities, the 
underlying pathology, other concurrent medications, or the cause of drug administration. In 
addition, these drugs are prescribed in many circumstances as prophylaxis for metastasis in cancer 
patients not due to the bad condition of the underlying pathology. 
The SF-12 is a multi-item survey for measuring the general health domains, without being 
specific to any disease or treatment groups. It is a shorter version of the SF-36 questionnaire. The 
main objective of its development is to reproduce the SF-36 questionnaire PCS and MCS. Many 
studies have been carried out to validate SF-12 and many authors have found that it can successfully 
produce the PCS and MCS of SF-36 [30–33]. It can be applied for measuring the health status of the 
general population or clinical populations and also for comparing general populations and diseased 
groups [34]. 
The SF-12 consists of eight scales derived from 12 items, which contain a mixture of positively- 
and negatively-worded responses. The eight scales are physical functioning, role physical, body pain, 
general health, vitality, social functioning, role emotional, and mental health scales. The eight scales 
are derived from one or two items. Since a greater number items means better representation of the 
scales, only the summary measures (PCS and MCS) have been considered the most useful scores 
derived from SF-12 [27,34]. 
PCS and MCS can be calculated through a scoring algorithm and there are computerized scoring 
algorithms available for producing them in real time. For SF-36, the calculation is usually performed 
by summing up the item score of each scale, transforming the resulting scale score into a 0–100 range, 
standardizing the scale scores into z-scores, and multiplying them with factor scores derived from 
orthogonally rotated principal component analyses (PCA) from the American general population. 
All of these procedures are carried out separately for the eight scales. For the calculation of PCS, 
positive weights of the resulting products of physical scales and negative weights of mental scales 
are summed, and the same procedure is performed for MCS, but vice versa. Then, the two scores are 
computed as norm-based t-scores. [16,34] 
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Despite the frequent use of SF-12 and its advantages, some concerns have been reported and 
should be considered in the interpretation of the obtained results. First, SF-12 cannot provide detailed 
subscales, only summary scales (PCS and MCS). Second, concerns have been reported in regard to 
the standard scoring algorithms of PCS and MCS. This is because the summary scores of SF-12 are 
based on assuming that physical and mental health is uncorrelated, despite the contribution of all 12 
items in the calculation of both PCS and MCS. Third, the items with responses representing higher 
PCS scores negatively affect the mental health scores (lower MCS) and vice versa. These points may 
lead to a decrease in the validity of these summary scores and the outcome of decisions based on 
these scores may not be achieved [16,27,28]. 
One of the main advantages of SF-12 is that a person does not need particular experience to use 
it. Moreover, SF-12 can be administrated in different modes, such as static (paper), online, or 
interactive voice response modes. The administration of SF-12 can be performed through self-
administration or interviewer administration. The preferred administration type is the face to face 
interview, as several studies have demonstrated a bias for low summary scores with self-
administration when compared to the interviewer type. SF-12 is also characterized as having a 
minimal respondent burden. It was found that 2–3 min were needed to complete it, which was about 
one third of the time needed for the completion of SF-36, as an example [34]. 
Some limitations were observed in this study that should be considered in future studies. First, 
the number of patients should be increased. Second, a disease-free control group would be useful for 
precisely evaluating the QoL of cancer patients with MRONJ. Further studies should test the SF-12 
and other QoL instruments to validate and develop a specific questionnaire for evaluating QoL in 
MRONJ patients. The inclusion of other risk factors may improve the quality of the study in the 
evaluation of QoL in MRONJ patients, such as comorbidities (e.g., diabetes), concurrent medications 
(e.g., corticosteroids), and smoking. 
5. Conclusions 
This study highlights the possible need for including psychosocial and physical evaluations in 
the management process of MRONJ in cancer patients. Further studies using other QoL instruments 
with a higher number of patients and a disease-free control group are needed to observe the effect of 
MRONJ on the QoL of cancer patients. 
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